Double blind controlled clinical trial of radiation plus razoxane (ICRF 159) versus radiation plus placebo in the treatment of head and neck cancer.
D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D010919:Placebos; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D011878:Radiotherapy / Q000009:adverse effects; D011929:Razoxane / Q000009:adverse effects / Q000627:therapeutic use*; D012468:Salivary Gland Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*
D010879:Piperazines; D010919:Placebos; D011838:Radiation-Sensitizing Agents; D011929:Razoxane